European Commission approves Pluvicto™
European Commission Approves Pluvicto for PSMA-Positive mCRPC OncLive, Dec 14, [...]
Lu-177-PSMA-617 approved by FDA for prostate cancer patients
Novartis has obtained US Food and Drug Administration (FDA) marketing [...]
FDA for Lu-177-PSMA-617 for mCRPC treatment
Targeted Oncology, Sarah Karlovitch, June 17, 2021 The FDA has [...]
Drugmakers push into radio pharmaceuticals
Dolgin, E. Drugmakers go nuclear, continuing push into radiopharmaceuticals. Nat Biotechnol 39, 647–649 [...]
Asco 2021 justifies Novartis’s radioligand Vision
Evaluate Vantage, Jacob Plieth, June 3, 2021 177Lu-PSMA-617 significantly improves [...]